NCCN 2017 Congress Series™: Biomarkers 101 - How Is Biomarker Testing Enriching Patient Populations for Clinical Trials & Impacting Drug Development?

November 9, 2017

Join Ross Camidge, MD, PhD, University of Colorado Cancer Center for this webinar How Is Biomarker Testing Enriching Patient Populations for Clinical Trials and Impacting Drug Development? in the NCCN 2017 Congress Series™: Biomarkers 101.

The science and practice of oncology are rapidly evolving based on more complete knowledge of cancer genomes and the specific genetic events that drive cancer. This knowledge, coupled with advances in medicinal chemistry, has ushered in an era of precision oncology. Use of molecular testing followed by therapies tailored to the particular molecular landscape of a patient’s disease can allow appropriate therapies to be given to patients who are most likely to benefit, while avoiding unnecessary treatment of patients who are unlikely to benefit.  Although the availability of new cancer biomarkers is encouraging for diagnosis, prognosis and treatment decision-making, determining the clinical usefulness and selection of the appropriate testing methodologies can represent a daunting challenge for practitioners.  With the field of biomarkers rapidly advancing, clinical research directly affects how oncologists manage patients. Keeping up with advances in biomarker testing allows clinicians to offer state-of-the-art care to their patients with cancer and to better identify patients that are appropriate for biomarker-directed clinical trials.

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss challenges with the identification of subsets of patients with mutations appropriate for study.
  • Explain how biomarker testing/molecular profiling can improve screening for clinical trials and enhance accrual.
  • Review results of biomarker-driven clinical trials.
  • Identify circumstances under which Next Generation Sequencing (NGS) methods are appropriate for biomarker testing.
Additional information
Supporters: 

This activity is supported by educational funding provided by Amgen.

This activity is supported by independent educational grants from AbbVie and Merck & Co., Inc.

This activity is supported by an independent medical education grant from Bristol-Myers Squibb.

This activity is supported by educational grants from:

  • AstraZeneca
  • Daiichi Sankyo, Inc.
  • Foundation Medicine
  • Genomic Health, Inc.
  • Lilly
  • Novartis
Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
10/12/2017
Course expires: 
01/06/2018
Event starts: 
11/09/2017 - 1:30pm
Event ends: 
11/09/2017 - 2:30pm
Cost:
$0.00

Ross Camidge, MD, PhD
University of Colorado Cancer Center

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-118-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
10/12/2017
Course expires: 
01/06/2018

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing